Company Description
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer.
The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc"R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.
Its product pipeline also includes inupadenant, a next-generation A2AR antagonists that is in Phase 1/2a clinical trials to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment; and EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation is in Phase 1 clinical trials.
Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
| Country | United States |
| Founded | 2011 |
| IPO Date | Jul 24, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 157 |
| CEO | Dr. Michel Detheux Ph.D. |
Contact Details
Address: 321 Arsenal Street, Bldg 312, Floor 3, Suite 301 Watertown, Massachusetts 02472 United States | |
| Phone | 857-204-4583 |
| Website | iteostherapeutics.com |
Stock Details
| Ticker Symbol | ITOS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 0001808865 |
| CUSIP Number | 46565G104 |
| ISIN Number | US46565G1040 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michel Detheux Ph.D. | President, Chief Executive Officer and Director |
| Matthew A. Call M.B.A. | Chief Operating Officer |
| Matthew Gall | Chief Financial Officer |
| Dr. Yvonne McGrath Ph.D. | Chief Scientific Officer |
| Adi Osovsky | Vice President and Head of Legal |
| Phillipe Brantegem | Vice-President of Human Resources |
| Dr. Joyson Joseph Karakunnel FACP, M.D., M.Sc. | Interim Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 25, 2024 | ARS | Filing |
| Apr 25, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 25, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 6, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 6, 2024 | 10-K | Annual Report |
| Feb 16, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 23, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 10, 2024 | 8-K | Current Report |